| |
Explore new possibilities with Fortrea. Oncology drug development informed by years of insights and powered by our agile approach to clinical trials. Explore Agility.
|
|
Today’s Big NewsNov 28, 2023 |
|
With Cytiva™️ Protein Select™️ resin, you will finally be able to standardize recombinant protein purification with a platform process. Request information.
|
|
| By Annalee Armstrong Acelyrin sent a chill rippling through the IPO market in September when its phase 3 clinical trial unexpectedly failed. But now the company says some errors by the contract research organization running the study may have been to blame. |
|
|
|
By Nick Paul Taylor Merck & Co. has revealed data from a phase 3 trial designed to knock Pfizer’s pneumococcal vaccine off its perch. The vaccine candidate matched Prevnar 20 for shared serotypes and performed better for 10 of its 11 unique serotypes, positioning Merck to file for approvals around the world. |
By Annalee Armstrong Aldeyra Therapeutics had prepared for the worst and now it's here. The FDA has rejected the dry eye drug reproxalap. |
Sponsored by WCG Pediatric CGT trials have the potential to cure diseases and prolong lives. Discover steps to protect safety and enhance operations in your CGT trials. |
By Annalee Armstrong Bristol Myers Squibb seems to have found a friend in Avidity Biosciences, as the two add a second link to a heart-focused research partnership for $100 million upfront. |
By James Waldron Boehringer Ingelheim will harness an artificial intelligence model trained in the computer labs of IBM as the German drugmaker becomes the latest Big Pharma to apply machine learning tools to its drug discovery efforts. |
By Helen Floersh A new study in mice has found that CAR-Ts targeting a common solid tumor antigen, GRP78, work well in some cases, but an unusual resistance pattern must be overcome for broader efficacy. |
By Max Bayer Candel Therapeutics is taking difficult measures to keep its clinical flame burning, laying off 50% of its team as part of a wide scale restructuring meant to save cash for a couple of core programs. |
By Max Bayer Eli Lilly is set to open its third Gateway Labs location, this time in San Diego. The accelerator-like space with allow local biotechs and researchers to tap into Lilly's expertise and burgeoning pocketbook. |
By Kevin Dunleavy It was the second straight quarter where the overwhelming success of blood sugar regulating treatments were the dominant story in the biopharma industry. Eli Lilly and Novo Nordisk delivered the highest revenue gains, at 38% and 29%, respectively. |
By Conor Hale Companies such as GE HealthCare, Siemens Healthineers, Philips and Hologic aim to keep the momentum in AI going at the annual radiology and digital imaging meeting. |
By Heather Landi Hospitals in multiple states have been forced to divert ambulances and reschedule some elective procedures after U.S. hospital owner Ardent Health Services was hit with a ransomware attack. |
By Angus Liu Patients with ultra-rare desmoid tumors now have an FDA-approved treatment, thanks to a drug made by SpringWorks Therapeutics, which spun out of Pfizer in 2017 with a portfolio of rare disease candidates. |
Fierce podcastsDon’t miss an episode |
| This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge. |
|
|---|
|
|
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
